Valink Therapeutics
PrivateLast Round
Series Pre-A
Oct 20, 2025
Est. Valuation
$12.6M
Total Funding Raised
$19.73M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Valink Therapeutics operates in Healthcare & Life Sciences and is based in London. Its latest recorded funding round was a Series Pre-A round in October 2025.
Valink Therapeutics is a biotechnology company that develops next-generation, antibody-based therapeutics, specifically bispecific antibody-drug conjugates (bsADCs), to treat solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Valink Therapeutics Comparables
Compare Valink Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Promatix Biosciences | 86% | |
| Allink Biotherapeutics | 81% | |
| Sidewinder Therapeutics | 81% |
For institutional investors. Book with your work email.
Valink Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series Pre-A | Oct 20, 2025 | ||||
| Seed | Nov 2, 2023 | ||||
| Accelerator | Mar 24, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Valink Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Saras Capital | Series Pre-A |
| Magnet Ventures | Seed |
| Metaplanet Holdings | Seed |
| Oxford Science Enterprises | Series Pre-A |
| Acequia Capital | Seed |
| Hoxton Ventures | Seed, Series Pre-A |
| Oxonian Ventures | Seed, Series Pre-A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors grew 1498% MoM, reaching 1.8K.
- Dec 17, 2025
Partnered with Nona Biosciences for integrated drug discovery solutions.
For institutional investors. Book with your work email.
Valink Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Valink Therapeutics's valuation, stock price, and market status.
Is Valink Therapeutics a public or private company?
Valink Therapeutics is a private company.
What is the current stock price of Valink Therapeutics?
Valink Therapeutics is a private company, so its shares have no public market price. Caplight tracks Valink Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Valink Therapeutics worth (valuation)?
Valink Therapeutics's valuation is estimated at $12.6M based on funding round data.
Can I buy Valink Therapeutics stock?
Valink Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Valink Therapeutics's last funding round?
Valink Therapeutics's most recent funding round was Series Pre-A on October 20, 2025.
Who are the main investors in Valink Therapeutics?
Key investors in Valink Therapeutics include Y Combinator, RV Invest, Redalpine.
Will Valink Therapeutics IPO soon?
No public IPO plans have been announced for Valink Therapeutics.
How can I track Valink Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Valink Therapeutics's shares on secondary markets.